RxDoctor Payments Data

Michael Desouza, MD

Internal Medicine · Orange City, FLNPI 1649292020

Payments from drug & device makers

$1,084in general payments, 2019–2025

Across 17 payments — averaging $63.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$250
  • Novo Nordisk$166
  • AbbVie$134
  • Abbott$125
  • Amgen$122
  • Medtronic$105
  • plus $181 from 3 others

What the payments were for

  • Food & beverage$1,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,084 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$134,323
Medicare patients
329
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$77,636
EliquisApixaban63$57,590
TrulicityDulaglutide18$34,681
JanuviaSitagliptin Phosphate19$28,349
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$21,451
BrilintaTicagrelor26$17,514
XareltoRivaroxaban12$14,304
Tresiba Flextouch U-100Insulin Degludec23$11,825
SymbicortBudesonide/Formoterol Fumarate38$10,666
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$8,026
Spiriva HandihalerTiotropium Bromide12$7,007
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen164$6,947
LevemirInsulin Detemir25$6,040
Combivent RespimatIpratropium/Albuterol Sulfate12$5,894
Advair HfaFluticasone Propion/Salmeterol13$5,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$166$83,67674 claims
GSKTrelegy Ellipta, Incruse Ellipta$61$25,73024 claims
Johnson & JohnsonXarelto$250$14,30412 claims
AbbVieSynthroid$134$3,21123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →